# Improving Anticancer Activity of Doxorubicin by 4′-epi-Dehydroxyamination

## TL;DR

Scientists modified doxorubicin to create a new compound that is more effective against drug-resistant cancer cells.

## Contribution

A novel synthetic modification of doxorubicin improves its anticancer activity by avoiding efflux pump resistance.

## Key findings

- Doxorubamine shows improved activity against both drug-sensitive and resistant cancer cells.
- Doxorubamine is a poor substrate of P-glycoprotein, making it effective against multidrug-resistant cancer.
- The modification offers a new strategy to bypass efflux pump resistance in cancer treatment.

## Abstract

Efflux pump-mediated multidrug resistance is a common
mechanism
by which cancer cells reduce the efficacy of a broad range of small-molecule
therapeutics. We discovered that substituting the 4′-hydroxy
group of doxorubicina known efflux pump substratewith
an epi-amino group results in a new compound, doxorubamine,
which exhibits substantially improved activity against drug-sensitive
and -resistant cancer cells and organoids. Mechanistic studies reveal
that doxorubamine is a poor substrate of P-glycoprotein, and it thus
retains high potency against multidrug-resistant cancer. This synthetic
modification provides a promising strategy for circumventing multidrug
resistance beyond conventional approaches that rely on efflux pump
inhibition.